NANECH
NanoEcho AB (publ) engages in developing diagnostic method to investigate the spread of rectal cancer to nearby lymph nodes. The company was incorporated in 2013 and is based in Lund, Sweden.
NANECH (NANECH) - Net Assets
Latest net assets as of December 2025: Skr14.73 Million SEK
Based on the latest financial reports, NANECH (NANECH) has net assets worth Skr14.73 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr18.42 Million) and total liabilities (Skr3.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr14.73 Million |
| % of Total Assets | 80.0% |
| Annual Growth Rate | 8.62% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 34.5 |
NANECH - Net Assets Trend (2022–2025)
This chart illustrates how NANECH's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NANECH (2022–2025)
The table below shows the annual net assets of NANECH from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr14.73 Million | -20.26% |
| 2024-12-31 | Skr18.47 Million | -0.12% |
| 2023-12-31 | Skr18.50 Million | +60.89% |
| 2022-12-31 | Skr11.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NANECH's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9992300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr114.66 Million | 778.23% |
| Total Equity | Skr14.73 Million | 100.00% |
NANECH Competitors by Market Cap
The table below lists competitors of NANECH ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MASCO - Dusseldorf Stock Exchang
DU:MSQ
|
$508.23K |
|
Lexston Mining Corporation
F:L75
|
$508.44K |
|
Rajdarshan Industries Limited
NSE:ARENTERP
|
$508.55K |
|
I Synergy Group Ltd
AU:IS3
|
$508.69K |
|
PAN AMER SILVER - Dusseldorf Stock Exchang
DU:PA2
|
$507.80K |
|
The Connecticut Light and Power Company
PINK:CNTHP
|
$506.99K |
|
Ottobock SE & Co. KGaA
XETRA:OBCK
|
$506.17K |
|
BRIT AMER TOBACCO
MU:BMT
|
$506.17K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NANECH's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,473,000 to 14,733,000, a change of -3,740,000 (-20.2%).
- Net loss of 15,654,000 reduced equity.
- New share issuances of 4,639,000 increased equity.
- Other factors increased equity by 7,275,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-15.65 Million | -106.25% |
| Share Issuances | Skr4.64 Million | +31.49% |
| Other Changes | Skr7.28 Million | +49.38% |
| Total Change | Skr- | -20.25% |
Book Value vs Market Value Analysis
This analysis compares NANECH's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.36x to 0.50x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | Skr0.07 | Skr0.02 | x |
| 2023-12-31 | Skr0.11 | Skr0.02 | x |
| 2024-12-31 | Skr0.09 | Skr0.02 | x |
| 2025-12-31 | Skr0.05 | Skr0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NANECH utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3207.79%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.25x
- Recent ROE (-106.25%) is below the historical average (-102.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -144.47% | 0.00% | 0.00x | 1.25x | Skr-17.76 Million |
| 2023 | -78.04% | 0.00% | 0.00x | 1.18x | Skr-16.28 Million |
| 2024 | -81.99% | 0.00% | 0.00x | 1.80x | Skr-16.99 Million |
| 2025 | -106.25% | -3207.79% | 0.03x | 1.25x | Skr-17.13 Million |
Industry Comparison
This section compares NANECH's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NANECH (NANECH) | Skr14.73 Million | -144.47% | 0.25x | $508.18K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |